IP Library › Granted Patent US 12,459,829
Granted Patent B2
US 12,459,829 · App. 17/291,763 · Granted Nov 4, 2025

Amorphous active pharmaceutical ingredients comprising substantially amorphous mesoporous magnesium carbonate

Inventors: Sara Frykstrand Ångström (Uppsala, SE); Ottilia Arvén (Uppsala, SE); Tuulikki Lindmark (Uppsala, SE); Peter Åsberg (Stockholm, SE)
Assignee: DISRUPTIVE PHARMA AB
C01F5/24A61K9/0053A61K45/06C01F5/02C01P2002/02C01P2004/61C01P2006/12C01P2006/14C01P2006/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,459,829
App. No.
17/291,763
Granted
Nov 4, 2025
Kind
B2
Abstract

A solid and substantially amorphous admixture comprising Sorafenib as active pharmaceutical ingredient (API) and a particulate anhydrous and substantially amorphous mesoporous magnesium carbonate (MMC), a method for the manufacture thereof, and an oral pharmaceutical formulation comprising the solid substantially amorphous admixture.

Claims (16)

1 . A solid amorphous pharmaceutical admixture comprising an active pharmaceutical ingredient (API) in combination with a particulate anhydrous mesoporous magnesium carbonate (MMC), wherein the API is sorafenib.

2 . The solid amorphous pharmaceutical admixture (MMC-API admixture) according to claim 1 , wherein the amount of sorafenib is at least 20% by weight.

3 . An oral pharmaceutical formulation comprising the solid amorphous pharmaceutical admixture (MMC-API admixture) of claim 1 .

4 . An oral pharmaceutical formulation comprising the solid amorphous pharmaceutical admixture (MMC-API admixture) of claim 1 , further comprising a pharmaceutically and pharmacologically acceptable excipient, carrier, and/or diluent.

5 . A capsule comprising the oral pharmaceutical formulation of claim 3 .

6 . A tablet comprising the oral pharmaceutical formulation of claim 3 .

7 . A capsule comprising the oral pharmaceutical formulation of claim 4 .

8 . A tablet comprising the oral pharmaceutical formulation of claim 4 .

9 . An oral pharmaceutical formulation comprising the solid amorphous active pharmaceutical admixture (MMC-API admixture) of claim 2 .

10 . An oral pharmaceutical formulation comprising the solid amorphous pharmaceutical admixture (MMC-API admixture) of claim 2 further comprising a pharmaceutically and pharmacologically acceptable excipient, carrier, and/or diluent.

11 . A capsule comprising the oral pharmaceutical formulation of claim 9 .

12 . A tablet comprising the oral pharmaceutical formulation of claim 9 .

13 . A capsule comprising the oral pharmaceutical formulation of claim 10 .

14 . A tablet comprising the oral pharmaceutical formulation of claim 10 .

15 . A method for the treatment of cancer, the method comprising administering the solid amorphous active pharmaceutical admixture according to claim 1 to a subject in need of such treatment.

16 . A method for the treatment of cancer, the method comprising administering the solid amorphous active pharmaceutical admixture according to claim 2 to a subject in need of such treatment.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY ADDRESS PREVIOUSLY RECORDED AT REEL: 058827 FRAME: 0359. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 2, 2022
From: DISRUPTIVE MATERIALS PHARMA AB
To: DISRUPTIVE PHARMA AB
Reel/Frame 059096/0741 →
CHANGE OF NAME Recorded Jan 24, 2022
From: DISRUPTIVE MATERIALS PHARMA AB
To: DISRUPTIVE PHARMA AB
Reel/Frame 058827/0359 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2021
From: FRYKSTRAND ÅNGSTRÖM, SARA; ARVÉN, OTTILIA; LINDMARK, TUULIKKI; ÅSBERG, PETER
To: DISRUPTIVE MATERIALS PHARMA AB
Reel/Frame 057092/0752 →
Priority Claims (1)
SE 1851383-8 · Nov 7, 2018 · national
Continuity (2)
Provisional Application 62756628 · Nov 7, 2018
Related Publication 20220024777A1 · Jan 27, 2022
References Cited (58)
US 10034883B2 · Prinderre · 2018 [cited by applicant]
US 10508041B2 · Strömme · 2019 [cited by examiner]
US 11155469B2 · Strömme · 2021 [cited by examiner]
US 20140206717A1 · Higgins et al. · 2014 [cited by applicant]
US 20170246111A1 · Monsuur et al. · 2017 [cited by applicant]
US 20190127232A1 · Cheung et al. · 2019 [cited by applicant]
CN 103732216A · 2014 [cited by applicant]
CN 106667916A · 2017 [cited by applicant]
EP 3048104A1 · 2016 [cited by examiner]
JP 2016508104A · 2016 [cited by applicant]
WO WO2009100176A2 · 2009 [cited by examiner]
WO 2009133100A2 · 2009 [cited by applicant]
WO 2010050897A1 · 2010 [cited by applicant]
WO 2012072580A1 · 2012 [cited by applicant]
WO 2013025449A1 · 2013 [cited by applicant]
WO 2014013044A1 · 2014 [cited by applicant]
WO 2014078435A1 · 2014 [cited by applicant]
WO 2014087355A1 · 2014 [cited by applicant]
WO 2014120922A1 · 2014 [cited by applicant]
WO 2017055591A1 · 2017 [cited by applicant]
WO 2017121806A1 · 2017 [cited by applicant]
WO 2017174458A1 · 2017 [cited by applicant]
WO 2019073062A1 · 2019 [cited by applicant]
WO 2019158421A1 · 2019 [cited by applicant]
Zhang, P. et al. “Diffusion—Controlled Drug Release From the Mesoporous Magnesium Carbonate Upsalite®” Journal of Pharmaceutical Sciences 2016, 105, 657-663 (Year: 2016). [cited by examiner]
Liu et al. “Improving Oral Bioavailability of Sorafenib by Optimizing the “Spring” and “Parachute” Based on Molecular Interaction Mechanisms”, Mol. Pharmaceutics 2016, 13, 599-608. (Year: 2016). [cited by examiner]
Zhang et al. “Stabilisation of amorphous ibuprofen in Upsalite, a mesoporous magnesium carbonate, as an approach to increasing the aqueous solubility of poorly soluble drugs” International Journal of Pharmaceutics 2014,… [cited by examiner]
“Tukysa® Highlights of prescribing information”, revised Jan. 2023, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf (accessed Sep. 5, 2024) (Year: 2023). [cited by examiner]
Frykstrand et al., The formation of Upsalite™, a template-free, micro- and mesoporous amorphous and anhydrous magnesium carbonate nanostructure. Uppsala Universitet. PLoS One. 2013;8(7): Poster. [cited by applicant]
Ivarsson, Impact of molecular properties on the drug loading efficiency of mesoporous magnesium carbonate (Upsalite®). Uppsala Universitet. Degree Project in Pharmaceutics and Biopharmaceutics 30c, spring semester, 42 p… [cited by applicant]
Monsuur, Mesoporous Silica, Dry Amorphisation. 7th International Symposium of Solid Oral Dosage Forms. Slideshow, 45 pages, Apr. 7-9, 2019. [cited by applicant]
Northfell, Particle size dependency on release rate from mesoporous magnesium carbonate (Upsalite®). Uppsala Universitet. Master degree project in pharmaceutics and biopharmaceutics, 30.0 c, spring semester. 42 pages, (… [cited by applicant]
Zhang et al., Supersaturation of poorly soluble drugs induced by mesoporous magnesium carbonate. Eur J Pharm Sci. Oct. 10, 2016;93:468-74. [cited by applicant]
Zhang, Mesoporous magnesium carbonate as a drug delivery vehicle for stabilising amorphous drugs and regulating their release rate. Uppsala Universitet. Thesis, 70 pages, (2016). [cited by applicant]
Ahlen et al., Amorphous mesoporous magnesium carbonate as a functional support for UV-blocking semiconductor nanoparticles for cosmetic applications. ACS Omega. Feb. 28, 2019;4:4429-36. [cited by applicant]
Ahlstrom. Characterizing the state of water in an amorphous magnesium carbonate using Dielectric spectroscopy. Graduate Thesis, Uppsala University. May 2013, 26 pages. [cited by applicant]
Alhalaweh et al., Computational predictions of glass-forming ability and crystallization tendency of drug molecules. Mol Pharm. 2014;11:3123-32. [cited by applicant]
Alvebratt et al., A modified in situ method to determine release from a complex drug carrier in particle-rich suspensions. AAPS PharmSciTech. Oct. 2018;19(7):2859-65. [cited by applicant]
Arven. Using Upsalite® as drug delivery vehicle: Increasing the solubility of poorly soluble drugs by stabilizing their amorphous state. Graduate Thesis, Uppsala University. Oct. 2017, 54 pages. [cited by applicant]
Baird et al., A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci. Sep. 2010;99(9):3787-806. [cited by applicant]
Botha et al., DTA and FT-IR analysis of the rehydration of basic magnesium carbonate. J Therm Anal Cal. 2003;71:987-95. [cited by applicant]
Chaudhari et al., Mesoporous silica as a carrier for amorphous solid dispersion. Br J Pharm Res. 2017;16(6):1-19. [cited by applicant]
Cheung et al., Nanostructure and pore size control of template-free synthesized mesoporous magnsium carbonate. RSC Advances. 2016;6:74241-9. [cited by applicant]
Clark. X-ray diffraction data for compound in the system CaO—MgO—SiO2. J Am Ceramic Society (Refractories Division No. 11). Mar. 15, 1945;29(1):25-30. [cited by applicant]
Edueng et al., The need for restructuring the disordered science of amorphous drug formulations. Pharm Res. 2017;34:1754-72. [cited by applicant]
Forsgren et al., A template-free, ultra-adsorbing, high surface area carbonate nanostructure. PLOS ONE. Jul. 2013;8(7):e68486. [cited by applicant]
Frykstrand et al., The formation of Upsalite(TM), a template-free, micro- and mesoporous amorphous and anhydrous magnesium carbonate nanostructure. Poster Presentation, Uppsala University. 2013, 1 page. [cited by applicant]
Frykstrand. Mesoporous magnesium carbonate synthesis, characterization and biocompatibility. Ph.D. Thesis, Uppsala University. May 20, 2016, 76 pages. [cited by applicant]
Mahlin et al., Early drug development predictions of glass-forming ability and physical stability of drugs. Eur J Pharm Sci. 2013;49:323-32. [cited by applicant]
Meyer et al., Comparison between different presentations of pore size distribution in porous materials. Fresenius J Anal Chem. 1999;363:174-8. [cited by applicant]
Notfors. Functionalization of Upsalite® with TiO2 for UV-blocking applications. Graduate Thesis, Uppsala University. Jun. 2016, 67 pages. [cited by applicant]
Scott et al., Magnesite formation from MgO and CO2 at the pressures and temperatures of Earth's mantle. American Mineralogist. 2013;98:1211-8. [cited by applicant]
Turova et al., Alcohol derivatives of the alkali and alkaline earth metals, magnesium, and thallium(I). Russ Chem Rev. Mar. 1965;34(3):161-85. [cited by applicant]
West et al., In Situ Formation of Alkylcarbonic Acids with CO2. J Phys Chem A. 2001;105:3947-8. [cited by applicant]
Yang et al., Amorphous magnesium carbonate nanoparticles with strong stabilizing capability for amorphous ibuprofen. Int J Pharm. Sep. 5, 2018;548(1):515-21. [cited by applicant]
Yang et al., Enhanced release of poorly water-soluble drugs from synergy between mesoporous magnesium carbonate and polymers. Int J Pharm. Jun. 15, 2017;525(1):183-190. [cited by applicant]
Zhang et al., Diffusion-controlled drug release from the mesoporous magnesium carbonate upsalite®. J Pharm Sci. Feb. 1, 2016;105(2):657-63. [cited by applicant]
Zhang et al., Stabilisation of amorphous ibuprofen in Upsalite, a mesoporous magnesium carbonate, as an approach to increasing the aqueous solubility of poorly soluble drugs. Int J Pharm. 2014;472:185-91. [cited by applicant]